Trial of Fulvestrant, MK-0646, and Dasatinib for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer

• Sponsor: M.D. Anderson Cancer Center (Other)
• Overall Status: Terminated
• CT.gov ID: NCT00903006
• Collaborator: Bristol-Myers Squibb (Industry), Merck Sharp & Dohme LLC (Industry), Commonwealth Foundation for Cancer Research (Other)
• Enrollment: 11
• Location: 1
• Arms: 4
• Duration (Months): 42
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

The goals of this clinical research study are to learn the tolerable and effective doses of the drug MK-0646 that can be given in combination with Sprycel (dasatinib) and Faslodex (fulvestrant) to patients with hormone receptor-positive metastatic breast cancer. The safety of these drugs will be studied as well as markers in the tumors that may help researchers predict the tumors' reaction to the treatment.

Condition or Disease	Intervention/Treatment	Phase
Breast Cancer	Drug: Fulvestrant; Drug: MK-0646; Drug: Dasatinib	Phase 1/Phase 2

Detailed Description

The Study Drugs:

Fulvestrant is designed to block estrogen from helping breast cancer tumor cells grow. By blocking estrogen, it may stop tumor growth.

Dasatinib is designed to change the function of genes. By changing the function of these genes, it may prevent cancer from growing and spreading.

MK-0646 is designed to block proteins that help breast cancer cells grow. By blocking these proteins, it may cause the cancer cells to die.

Study Procedures:

You will have a fine needle aspiration or core needle biopsy before you start the study treatment and after 2 weeks. These biopsies are to study genes and proteins, and to see how they change with treatment.

Study Groups:

If you are found to be eligible to take part in this study: you will be enrolled in Phase I or Phase II of the study, depending on when you join the study.

If you are in Phase I, you will be assigned to either Group 1, 2, 3, or 4. If you are in Phase II, (based on the result of the screening biopsy) you will be randomly assigned (as in a roll of dice) to either Group 1, 2, 3, or 4:

• Group 1 will receive fulvestrant only.

• Group 2 will receive fulvestrant and dasatinib.

• Group 3 will receive fulvestrant and MK-0646.

• Group 4 will receive fulvestrant, MK-0646, and dasatinib.

All participants will receive the same dose level of fulvestrant.

If you are in Groups 2, 3, or 4, the dose of MK-0646 and/or dasatinib you receive will depend on when you joined this study. The first set of participants in each group will receive the lowest dose level of MK-0646 and/or dasatinib. Each new set will receive a higher dose of MK-0646 and/or dasatinib than the set before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of MK-0646 and/or dasatinib is found. This is called the Phase I portion of the study.

If you are enrolled in the Phase II portion of the study, you will receive dasatinib at the dose that was tolerated in the Phase I portion.

Study Drug Administration:

Every 28 days makes up 1 study cycle.

You will receive fulvestrant through a needle into your muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. You will have 2 injections each time into 2 different muscles.

If you are in Group 3 or Group 4, you will receive MK-0646 through a needle in your vein weekly.

If you are in Group 2 or Group 4, you will take capsules of dasatinib by mouth every day while you are on study. You should take the drug at about the same time each day with a cup (8 ounces) of water. The study staff will give you a card on which you must record every time that you take dasatinib.

Study Visits:

On Day 1 of every cycle for the first 4 cycles, and then every 3 cycles, the following tests and procedures will be performed:

• You will have a physical exam, including measurement of your weight.

• Your performance status will be recorded.

• You will be asked about any other drugs you may be taking.

• Blood (about 1 tablespoon) will be drawn for routine tests and to see how your immune system may be responding to the study drug.

On Day 1 of each cycle, the following procedure will be performed:

-You will be asked about any side effects you may be having.

On Day 1 of Cycle 1, your vital signs will be measured.

On Days 8 and 22 of Cycle 1, your vital signs and weight will be measured. You will have an ECG.

On Day 15 of Cycle 1, the following tests and procedures will be performed:

• Your vital signs and weight will be measured.

• You will have an ECG.

• You will have a PET scan

• You will have a core needle biopsy (which removes more tissue) and/or a fine needle aspiration (which has a smaller needle).

On Days 1, 8, 15, and 22 of Cycles 2 and beyond, your weight will be measured.

On Day 1 of Cycle 4 and every 3 cycles after that, you will have CT scans of the chest, abdomen and/or pelvis, to check the status of the disease. If the disease has spread, you may also have a bone scan and/or x-rays of the bones.

If you are taking warfarin to prevent abnormal blood clotting, blood (about 1-2 teaspoons) will be drawn to check your blood clotting function at least 1 time a week until your blood clotting function becomes stable. After that, blood (about 1-2 teaspoons) will continue being drawn to check your blood clotting function as often as the doctor decides is needed.

Length of Study:

You may receive the study therapy until either you experience intolerable side effects or if the disease gets worse; then you will be taken off study.

End-of-Study Visit:

After you are off study, you will have an end-of-study visit. At this visit, the following tests and procedures will be performed:

• You will have a physical exam, including measurement of your vital signs and weight.

• You will be asked about any other drugs you may be taking and about any side effects you may be having.

• Your performance status will be recorded.

• Blood (about 2 teaspoons) will be collected for routine tests.

• You will have a hearing test if you received MK-0646.

Four (4), 8, and 12 weeks after the last dose of study drug, blood (about 1 tablespoon) will be drawn to see how your immune system may have responded to the study drug.

This is an investigational study. MK-0646 is not FDA-approved or commercially available. At this time, MK-0646 is only being used in research. Fulvestrant is currently FDA -approved and commercially available for the treatment of metastatic breast cancer in post-menopausal women. Dasatinib is FDA-approved and commercially available to treat chronic myeloid leukemia. At this time, the use of dasatinib in breast cancer patients is investigational.

Up to 40 patients will take part in this study at University of Texas (UT) MD Anderson Cancer Center.

Study Design

• Study Type: Interventional
• Actual Enrollment: 11 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I-II, Randomization, Open-Label Clinical Trial of Fulvestrant Versus the Combination of Fulvestrant, MK-0646, and Dasatinib as First-Line Therapy for Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer
• Study Start Date: Nov 1, 2009
• Actual Primary Completion Date: May 1, 2013
• Actual Study Completion Date: May 1, 2013

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Group 1: Fulvestrant Group 1 will receive Fulvestrant only.	Drug: Fulvestrant; Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.; Other Names: Faslodex
Active Comparator: Group 2: Fulvestrant + Dasatinib Group 2 will receive Fulvestrant and Dasatinib.	Drug: Fulvestrant; Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.; Other Names: Faslodex ; Drug: Dasatinib; Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.; Other Names: BMS-354825 Sprycel
Active Comparator: Group 3: Fulvestrant + MK-0646 Group 3 will receive Fulvestrant and MK-0646.	Drug: Fulvestrant; Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.; Other Names: Faslodex ; Drug: MK-0646; Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
Active Comparator: Group 4: Fulvestrant, MK-0646 + Dasatinib Group 4 will receive Fulvestrant, MK-0646, and Dasatinib.	Drug: Fulvestrant; Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.; Other Names: Faslodex ; Drug: MK-0646; Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.; Drug: Dasatinib; Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.; Other Names: BMS-354825 Sprycel

Outcome Measures

Primary Outcome Measures

1. Phase I Maximum Tolerated Dose (MTD) for Dose Level 1 [28 day cycle]

   Maximum Tolerated Dose (MTD) defined as the dose or dose-combination that has the mean posterior toxicity rate closest to the target toxicity rate of 0.33. Dose levels reviewed with each 28 day cycle. Treatment dose levels: Fulvestrant will be given using a loading dose of 500 mg intramuscularly (IM) on day 1 as two 250 mg/5 ml injections, followed by 500 mg IM on day 15 and on day 1 of each subsequent 28- day (+/- 2 days) cycle. MK-0646 will be given intravenously on days 1,8, 15, and 22 for each cycle at one of the two dose levels: 1) 5 mg/kg or 2) 10 mg/kg (Dose level 1) Dasatinib will be given orally (PO) continuously on days 1 -28 for each cycle at one of two dose levels: 1) 70 mg po daily or 2) 100 mg po daily

2. Patient Response (+ Time to Disease Progression) [Baseline, after two 28 day cycles, until disease progression.]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: Female
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. For the Phase I: Patients with histologically or cytologically confirmed diagnosis of metastatic hormone receptor-positive HER2-negative breast cancer who have received up to one line of endocrine therapy for metastatic disease.

2. Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)

3. Age >/= 18 years

4. Eastern Cooperative Oncology Group (ECOG) performance status of </= 2

5. Required laboratory values: Absolute neutrophil count (ANC)>/= 1500 cells/mm^{3, platelet count >/= 100,000 cells/mm}3, hemoglobin >/= 9 gm/L; bilirubin </= 1.5 * upper limit of normal (ULN), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </= 2.5 * ULN; serum creatinine </= 2.0 * ULN

6. Ability to understand the requirements of the study, provided written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

7. Patients must be postmenopausal (> 12 months of amenorrhea, bilateral oophorectomy).

8. Patients must have received prior anti-estrogen therapy in the adjuvant setting.

9. Patients may have easily accessible tumors for biopsy (confirmed by interventional radiology).

10. Patients must consent to biopsies.

11. For the Phase II: Patients with histologically or cytologically confirmed diagnosis of metastatic hormone receptor-positive, HER2-negative, breast cancer who have received up to one line of endocrine therapy for metastatic disease.

12. Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, or lesions which do not fulfill RECIST criteria for metastatic disease)

13. Age >/= 18 years

14. ECOG performance status of </= 2

15. Required Laboratory Values: ANC >/= 1500 cells/mm^{3, platelet count >/= 100,000 cells/mm}3, hemoglobin >/= 9 gm/L, Bilirubin </= 1.5 * ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </= 2.5 * ULN

16. Serum creatinine </= 2.0 * ULN

17. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments.

18. Patients must be postmenopausal (> 12 months of amenorrhea, bilateral oophorectomy).

19. Patients must have received prior anti-estrogen therapy in the adjuvant setting.

20. Patients may have easily accessible tumors for biopsy (confirmed by interventional radiology).

21. Patients must consent to biopsies.

Exclusion Criteria:

1. For the Phase I: History of prior malignancies within the past 5 years with the exception of curatively treated basal or squamous cell carcinomas of the skin or carcinoma in situ of the cervix

2. Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, ongoing or recent gastrointestinal bleed, hepatic or cardiac compromise, hypocalcemia, or known platelet function abnormality).

3. Concomitant medication known to prolong QT interval, unless discontinued >/= 7 days of starting dasatinib therapy.

4. Newly diagnosed (within 3 months before enrollment) or poorly controlled (defined as a fasting serum glucose > 160 mg/dl or hemoglobin A1c > 8% at screening), type 1 or 2 diabetes mellitus.

5. Active or untreated brain metastasis

6. Pleural or pericardial effusion of any grade

7. Bone only metastases

8. Patients for whom endocrine therapy is not appropriate (i.e. life threatening metastatic disease).

9. Patients requiring therapeutic anticoagulation (Warfarin 1 mg for port maintenance is allowed).

10. For the Phase II: History of prior malignancies within the past 5 years with the exception of curatively treated basal or squamous cell carcinomas of the skin or carcinoma in situ of the cervix

11. Concurrent severe or uncontrolled medical disease (i.e., systemic infection, diabetes, hypertension, coronary artery disease, congestive heart failure, ongoing or recent gastrointestinal bleed, hepatic or cardiac compromise, hypocalcemia, or known platelet function abnormality).

12. Concomitant medication known to prolong QT interval, unless discontinued >/= 7 days of starting dasatinib therapy.

13. Newly diagnosed (within 3 months before enrollment) or poorly controlled (defined as a fasting serum glucose > 160 mg/dl or hemoglobin A1c > 8% at screening), type 1 or 2 diabetes mellitus.

14. Active or untreated brain metastasis

15. Pleural or pericardial effusion of any grade

16. Bone only metastases

17. Patients for whom endocrine therapy is not appropriate (i.e. life threatening metastatic disease).

18. Patients requiring therapeutic anticoagulation (Warfarin 1 mg for port maintenance is allowed).

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	UT MD Anderson Cancer Center	Houston	Texas	United States	77030

Sponsors and Collaborators

• M.D. Anderson Cancer Center
• Bristol-Myers Squibb
• Merck Sharp & Dohme LLC
• Commonwealth Foundation for Cancer Research

Investigators

• Study Chair: Ana Gonzalez-Angulo, MD, MS, UT MD Anderson Cancer Center

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• UT MD Anderson Cancer Center website

Publications

None provided.

• Responsible Party: M.D. Anderson Cancer Center
• ClinicalTrials.gov Identifier: NCT00903006
• Other Study ID Numbers: 2008-0336
• First Posted: May 15, 2009
• Last Update Posted: Feb 2, 2015
• Last Verified: Jun 1, 2014

• Keywords provided by M.D. Anderson Cancer Center: Breast; Hormone receptor-positive metastatic breast cancer; Fulvestrant; Faslodex; MK-0646; Dasatinib; BMS-354825; Sprycel; Adjuvant hormonal therapy
• Additional relevant MeSH terms: Breast Neoplasms; Dasatinib; Fulvestrant

Study Results

Participant Flow

Recruitment Details	Recruitment Period: November 19, 2009 to February 13, 2012. All recruitment done in medical clinical at the University of Texas (UT) MD Anderson Cancer Center.
Pre-assignment Detail	Out of 11 participants registered to the trial, five (5) were screen failures and thus excluded from the trial. The Phase I portion of study began with the first three arms: 1) Fulvestrant, 2) Fulvestrant + Low Dose Dasatinib and 3) Fulvestrant + Low Dose of MK-0646.

Arm/Group Title	Group 1: Fulvestrant	Group 2: Fulvestrant + Dasatinib	Group 3: Fulvestrant + MK-0646	Group 4: Fulvestrant, MK-0646 + Dasatinib
Arm/Group Description	Group 1 will receive Fulvestrant only. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.	Group 2 will receive Fulvestrant and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.	Group 3 will receive Fulvestrant and MK-0646. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.	Group 4 will receive Fulvestrant, MK-0646, and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
Period Title: Overall Study
STARTED	2	3	1	0
COMPLETED	0	0	0	0
NOT COMPLETED	2	3	1	0

Baseline Characteristics

Arm/Group Title	Group 1: Fulvestrant	Group 2: Fulvestrant + Dasatinib	Group 3: Fulvestrant + MK-0646	Group 4: Fulvestrant, MK-0646 + Dasatinib	Total
Arm/Group Description	Group 1 will receive Fulvestrant only. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.	Group 2 will receive Fulvestrant and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.	Group 3 will receive Fulvestrant and MK-0646. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.	Group 4 will receive Fulvestrant, MK-0646, and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.	Total of all reporting groups
Overall Participants	2	3	1	0	6
Age (participants) [Number]
<=18 years	0 0%	0 0%	0 0%	0 NaN
Between 18 and 65 years	2 100%	2 66.7%	1 100%	5 Infinity
>=65 years	0 0%	1 33.3%	0 0%	1 Infinity
Age (years) [Median (Full Range) ]
Median (Full Range) [years]	51	63	36	57.5
Gender (participants) [Number]
Female	2 100%	3 100%	1 100%	6 Infinity
Male	0 0%	0 0%	0 0%	0 NaN
Ethnicity (NIH/OMB) (participants) [Number]
Hispanic or Latino	0 0%	1 33.3%	1 100%	2 Infinity
Not Hispanic or Latino	2 100%	2 66.7%	0 0%	4 Infinity
Unknown or Not Reported	0 0%	0 0%	0 0%	0 NaN
Race (NIH/OMB) (participants) [Number]
American Indian or Alaska Native	0 0%	0 0%	0 0%	0 NaN
Asian	1 50%	0 0%	0 0%	1 Infinity
Native Hawaiian or Other Pacific Islander	0 0%	0 0%	0 0%	0 NaN
Black or African American	0 0%	0 0%	0 0%	0 NaN
White	1 50%	3 100%	1 100%	5 Infinity
More than one race	0 0%	0 0%	0 0%	0 NaN
Unknown or Not Reported	0 0%	0 0%	0 0%	0 NaN
Region of Enrollment (participants) [Number]
United States	2 100%	3 100%	1 100%	6 Infinity

Outcome Measures

1. Primary Outcome

Title	Phase I Maximum Tolerated Dose (MTD) for Dose Level 1
Description	Maximum Tolerated Dose (MTD) defined as the dose or dose-combination that has the mean posterior toxicity rate closest to the target toxicity rate of 0.33. Dose levels reviewed with each 28 day cycle. Treatment dose levels: Fulvestrant will be given using a loading dose of 500 mg intramuscularly (IM) on day 1 as two 250 mg/5 ml injections, followed by 500 mg IM on day 15 and on day 1 of each subsequent 28- day (+/- 2 days) cycle. MK-0646 will be given intravenously on days 1,8, 15, and 22 for each cycle at one of the two dose levels: 1) 5 mg/kg or 2) 10 mg/kg (Dose level 1) Dasatinib will be given orally (PO) continuously on days 1 -28 for each cycle at one of two dose levels: 1) 70 mg po daily or 2) 100 mg po daily
Time Frame	28 day cycle

Outcome Measure Data

Analysis Population Description

Study terminated early; Analysis not available due to smaller sample size.

Arm/Group Title	Group 1: Fulvestrant	Group 2: Fulvestrant + Dasatinib	Group 3: Fulvestrant + MK-0646	Group 4: Fulvestrant, MK-0646 + Dasatinib
Arm/Group Description	Group 1 will receive Fulvestrant only. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.	Group 2 will receive Fulvestrant and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.	Group 3 will receive Fulvestrant and MK-0646. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.	Group 4 will receive Fulvestrant, MK-0646, and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
Measure Participants	0	0	0	0

2. Primary Outcome

Title	Patient Response (+ Time to Disease Progression)
Time Frame	Baseline, after two 28 day cycles, until disease progression.

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title

Arm/Group Description

Adverse Events

Time Frame	Adverse event evaluation through each 28 day cycle and 3-4 weeks after the last cycle. Overall study collection period May 2010 to January 2012.
Arm/Group Title	Group 1: Fulvestrant		Group 2: Fulvestrant + Dasatinib		Group 3: Fulvestrant + MK-0646		Group 4: Fulvestrant, MK-0646 + Dasatinib
Arm/Group Description	Group 1 will receive Fulvestrant only. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.		Group 2 will receive Fulvestrant and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.		Group 3 will receive Fulvestrant and MK-0646. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.		Group 4 will receive Fulvestrant, MK-0646, and Dasatinib. Fulvestrant: Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection. MK-0646: Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle. Dasatinib: Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
All Cause Mortality
	Group 1: Fulvestrant		Group 2: Fulvestrant + Dasatinib		Group 3: Fulvestrant + MK-0646		Group 4: Fulvestrant, MK-0646 + Dasatinib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	/ (NaN)		/ (NaN)		/ (NaN)		/ (NaN)
Serious Adverse Events
	Group 1: Fulvestrant		Group 2: Fulvestrant + Dasatinib		Group 3: Fulvestrant + MK-0646		Group 4: Fulvestrant, MK-0646 + Dasatinib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	1/2 (50%)		2/3 (66.7%)		0/1 (0%)		0/0 (NaN)
Metabolism and nutrition disorders
Hyperglycemia	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Musculoskeletal and connective tissue disorders
Gait abnormal	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Respiratory, thoracic and mediastinal disorders
Dyspnea	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Other (Not Including Serious) Adverse Events
	Group 1: Fulvestrant		Group 2: Fulvestrant + Dasatinib		Group 3: Fulvestrant + MK-0646		Group 4: Fulvestrant, MK-0646 + Dasatinib
	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events	Affected / at Risk (%)	# Events
Total	2/2 (100%)		3/3 (100%)		1/1 (100%)		0/0 (NaN)
Blood and lymphatic system disorders
Hyperglycemia	2/2 (100%)	5	2/3 (66.7%)	8	1/1 (100%)	1	0/0 (NaN)	0
Abnormal Blood Tests	2/2 (100%)	4	3/3 (100%)	12	0/1 (0%)	0	0/0 (NaN)	0
Lymphocyte absolute count decreased	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Hemoglobin decreased	1/2 (50%)	1	3/3 (100%)	4	0/1 (0%)	0	0/0 (NaN)	0
Neutrophil count decreased	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Cardiac disorders
Palpitations	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Endocrine disorders
Growth hormone abnormal	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Hot flashes	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Hypothyroidism	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Eye disorders
Red irritated eyes	0/2 (0%)	0	0/3 (0%)	0	1/1 (100%)	1	0/0 (NaN)	0
Retinopathy	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Gastrointestinal disorders
Anorexia	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Constipation	1/2 (50%)	1	1/3 (33.3%)	1	1/1 (100%)	1	0/0 (NaN)	0
Diarrhea	1/2 (50%)	1	2/3 (66.7%)	3	0/1 (0%)	0	0/0 (NaN)	0
Mucositis oral	0/2 (0%)	0	0/3 (0%)	0	1/1 (100%)	1	0/0 (NaN)	0
Nausea	1/2 (50%)	2	1/3 (33.3%)	3	1/1 (100%)	1	0/0 (NaN)	0
Vomiting	0/2 (0%)	0	1/3 (33.3%)	5	0/1 (0%)	0	0/0 (NaN)	0
General disorders
Burning Sensation in throat	0/2 (0%)	0	0/3 (0%)	0	1/1 (100%)	1	0/0 (NaN)	0
Fatigue	2/2 (100%)	3	3/3 (100%)	4	1/1 (100%)	1	0/0 (NaN)	0
Insomnia	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Sweating	1/2 (50%)	2	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Weight loss	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Immune system disorders
Hypersensitivity	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Infections and infestations
Infection	0/2 (0%)	0	1/3 (33.3%)	3	0/1 (0%)	0	0/0 (NaN)	0
Investigations
Fever	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Metabolism and nutrition disorders
Alanine aminotransferase increased	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Alkaline phosphatase increased	0/2 (0%)	0	2/3 (66.7%)	3	0/1 (0%)	0	0/0 (NaN)	0
Aspartate aminotransferase increased	1/2 (50%)	1	2/3 (66.7%)	2	0/1 (0%)	0	0/0 (NaN)	0
Hyperuricemia	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Creatinine increased	0/2 (0%)	0	2/3 (66.7%)	4	0/1 (0%)	0	0/0 (NaN)	0
Hypercalcaemia	0/2 (0%)	0	1/3 (33.3%)	3	0/1 (0%)	0	0/0 (NaN)	0
Metabolic disorders	2/2 (100%)	12	3/3 (100%)	20	1/1 (100%)	9	0/0 (NaN)	0
Serum glucose decrease	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Serum magnesium decreased	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Serum phosphate decreased	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Serum potassium increased	0/2 (0%)	0	0/3 (0%)	0	1/1 (100%)	1	0/0 (NaN)	0
Serum potassium decreased	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Serum sodium decreased	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Musculoskeletal and connective tissue disorders
Back pain	0/2 (0%)	0	1/3 (33.3%)	3	0/1 (0%)	0	0/0 (NaN)	0
Bone Pain, Generalized	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Edema limbs	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Fracture	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Gait abnormal	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Joint pain	0/2 (0%)	0	0/3 (0%)	0	1/1 (100%)	1	0/0 (NaN)	0
Muscle weakness	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Myalgia	1/2 (50%)	1	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Neck pain	0/2 (0%)	0	1/3 (33.3%)	3	0/1 (0%)	0	0/0 (NaN)	0
Pain	2/2 (100%)	8	2/3 (66.7%)	6	1/1 (100%)	1	0/0 (NaN)	0
Muscle Cramping	1/2 (50%)	1	0/3 (0%)	0	1/1 (100%)	2	0/0 (NaN)	0
Nervous system disorders
Dizziness	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Headache	1/2 (50%)	1	2/3 (66.7%)	3	1/1 (100%)	1	0/0 (NaN)	0
Paresthesia of the hand	1/2 (50%)	1	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Somnolence	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Neuropathy, Leg	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Psychiatric disorders
Anxiety	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Depression	1/2 (50%)	1	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Respiratory, thoracic and mediastinal disorders
Cough	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Dyspnea	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Pleural effusion	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Pressure Chest	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Pneumonia	0/2 (0%)	0	1/3 (33.3%)	1	0/1 (0%)	0	0/0 (NaN)	0
Skin and subcutaneous tissue disorders
Alopecia	1/2 (50%)	1	0/3 (0%)	0	0/1 (0%)	0	0/0 (NaN)	0
Bruising	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Rash/Keratosis	0/2 (0%)	0	1/3 (33.3%)	2	0/1 (0%)	0	0/0 (NaN)	0
Rash acneiform	1/2 (50%)	1	2/3 (66.7%)	4	0/1 (0%)	0	0/0 (NaN)	0

Limitations/Caveats

Study terminated early due to small sample size.

More Information

Certain Agreements

Principal Investigators are NOT employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.